Last reviewed · How we verify
Lispro Insulin and glargine insulin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lispro Insulin and glargine insulin (Lispro Insulin and glargine insulin) — Diabetes Care Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lispro Insulin and glargine insulin TARGET | Lispro Insulin and glargine insulin | Diabetes Care Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lispro Insulin and glargine insulin CI watch — RSS
- Lispro Insulin and glargine insulin CI watch — Atom
- Lispro Insulin and glargine insulin CI watch — JSON
- Lispro Insulin and glargine insulin alone — RSS
Cite this brief
Drug Landscape (2026). Lispro Insulin and glargine insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/lispro-insulin-and-glargine-insulin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab